SCM
RGLS

Soleus Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Soleus Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,562,500
Closed -$4.5M – 108
2024
Q1 		$4.5M Buy
+1,562,500
New +$2.55M 0.33% 67

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Soleus Capital Management's RGLS Position: Q2 2024 in Review

Soleus Capital Management sold out of Regulus Therapeutics (RGLS) in Q2 2024, closing a stake of 1,562,500 shares — an estimated $4.5M sold.

Soleus Capital Management first reported a position in RGLS in Q1 2024 and held it in 1 quarter. The position peaked at $4.5M in Q1 2024. 63 funds tracked by Wall St. Rank hold RGLS as of Q2 2024.

  • Soleus Capital Management reported no remaining Regulus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Soleus Capital Management sold 1,562,500 Regulus Therapeutics shares in Q2 2024, an estimated $4.5M.
  • Soleus Capital Management first reported a position in Regulus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Soleus Capital Management's Regulus Therapeutics position peaked at $4.5M in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2024.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.